Solid Biosciences Inc. Increase (Decrease) in Leasing Receivables
Solid Biosciences Inc. (SLDB) reported Increase (Decrease) in Leasing Receivables of -$823.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLeasingReceivables · last filed 2021-03-15
- Solid Biosciences Inc. increase (decrease) in leasing receivables for the quarter ending 2018-12-31 was $0.00.
- Solid Biosciences Inc. increase (decrease) in leasing receivables for fiscal 2018 was -$823.00K.
| Period end | Increase (Decrease) in Leasing Receivables 3 month | Increase (Decrease) in Leasing Receivables 9 month | Increase (Decrease) in Leasing Receivables 12 month |
|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$823.00K 10-K · filed 2021-03-15 | |
| 2018-09-30 | -$823.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |